#molnupiravir — Public Fediverse posts

#SARS-CoV-2 Error Catastrophe Under #Molnupiravir: #Mutagenic Enhancement Enables Viral #Persistence with Impaired Fitness, https://etidiohnew.blogspot.com/2026/02/sars-cov-2-error-catastrophe-under.html

#SARS-CoV-2 Error Catastrophe Under #Molnupiravir: #Mutagenic Enhancement Enables Viral #Persistence with Impaired Fitness, https://etidiohnew.blogspot.com/2026/02/sars-cov-2-error-catastrophe-under.html

#SARS-CoV-2 Error Catastrophe Under #Molnupiravir: #Mutagenic Enhancement Enables Viral #Persistence with Impaired Fitness, https://etidiohnew.blogspot.com/2026/02/sars-cov-2-error-catastrophe-under.html

#SARS-CoV-2 Error Catastrophe Under #Molnupiravir: #Mutagenic Enhancement Enables Viral #Persistence with Impaired Fitness, https://etidiohnew.blogspot.com/2026/02/sars-cov-2-error-catastrophe-under.html

#SARS-CoV-2 Error Catastrophe Under #Molnupiravir: #Mutagenic Enhancement Enables Viral #Persistence with Impaired Fitness, https://etidiohnew.blogspot.com/2026/02/sars-cov-2-error-catastrophe-under.html

Effectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html

Effectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html

Effectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html

Effectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html

Effectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html

#Molnupiravir clinical trial simulation suggests that #PCR underestimates #antiviral #potency against #SARS-CoV-2, https://etidiohnew.blogspot.com/2025/11/molnupiravir-clinical-trial-simulation.html

#Molnupiravir clinical trial simulation suggests that #PCR underestimates #antiviral #potency against #SARS-CoV-2, https://etidiohnew.blogspot.com/2025/11/molnupiravir-clinical-trial-simulation.html

#Molnupiravir clinical trial simulation suggests that #PCR underestimates #antiviral #potency against #SARS-CoV-2, https://etidiohnew.blogspot.com/2025/11/molnupiravir-clinical-trial-simulation.html

#Molnupiravir clinical trial simulation suggests that #PCR underestimates #antiviral #potency against #SARS-CoV-2, https://etidiohnew.blogspot.com/2025/11/molnupiravir-clinical-trial-simulation.html

#Molnupiravir clinical trial simulation suggests that #PCR underestimates #antiviral #potency against #SARS-CoV-2, https://etidiohnew.blogspot.com/2025/11/molnupiravir-clinical-trial-simulation.html

#Molnupiravir inhibits #Bourbon virus #infection and disease-associated #pathology in mice, https://etidiohnew.blogspot.com/2025/09/molnupiravir-inhibits-bourbon-virus.html

#Molnupiravir inhibits #Bourbon virus #infection and disease-associated #pathology in mice, https://etidiohnew.blogspot.com/2025/09/molnupiravir-inhibits-bourbon-virus.html

#Molnupiravir inhibits #Bourbon virus #infection and disease-associated #pathology in mice, https://etidiohnew.blogspot.com/2025/09/molnupiravir-inhibits-bourbon-virus.html

#Molnupiravir inhibits #Bourbon virus #infection and disease-associated #pathology in mice, https://etidiohnew.blogspot.com/2025/09/molnupiravir-inhibits-bourbon-virus.html

#Molnupiravir inhibits #Bourbon virus #infection and disease-associated #pathology in mice, https://etidiohnew.blogspot.com/2025/09/molnupiravir-inhibits-bourbon-virus.html

#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html

#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html

#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html

#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html

#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html

The combinatorial activities of #oseltamivir and #molnupiravir against #influenza virus infections in vitro and in vivo, https://etidiohnew.blogspot.com/2025/07/the-combinatorial-activities-of.html

The combinatorial activities of #oseltamivir and #molnupiravir against #influenza virus infections in vitro and in vivo, https://etidiohnew.blogspot.com/2025/07/the-combinatorial-activities-of.html

The combinatorial activities of #oseltamivir and #molnupiravir against #influenza virus infections in vitro and in vivo, https://etidiohnew.blogspot.com/2025/07/the-combinatorial-activities-of.html

The combinatorial activities of #oseltamivir and #molnupiravir against #influenza virus infections in vitro and in vivo, https://etidiohnew.blogspot.com/2025/07/the-combinatorial-activities-of.html

The combinatorial activities of #oseltamivir and #molnupiravir against #influenza virus infections in vitro and in vivo, https://etidiohnew.blogspot.com/2025/07/the-combinatorial-activities-of.html

#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html

#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html

#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html

#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html

#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html

https://www.cidrap.umn.edu/covid-19/delays-covid-antiviral-receipt-raised-risk-poor-outcomes-after-ed-visits-18-data-suggest #science #medicine #healthcare #COVID #COVID19 #Remdesivir #Veklury #nirmatrelvir #ritonavir #Paxlovid #sotrovimab #Xevudy #molnupiravir #Lagevrio

https://www.cidrap.umn.edu/covid-19/delays-covid-antiviral-receipt-raised-risk-poor-outcomes-after-ed-visits-18-data-suggest #science #medicine #healthcare #COVID #COVID19 #Remdesivir #Veklury #nirmatrelvir #ritonavir #Paxlovid #sotrovimab #Xevudy #molnupiravir #Lagevrio

https://www.cidrap.umn.edu/covid-19/delays-covid-antiviral-receipt-raised-risk-poor-outcomes-after-ed-visits-18-data-suggest #science #medicine #healthcare #COVID #COVID19 #Remdesivir #Veklury #nirmatrelvir #ritonavir #Paxlovid #sotrovimab #Xevudy #molnupiravir #Lagevrio

Health #outcomes 3 mos & 6 mos after #molnupiravir treatment for #COVID19 for people at higher #risk in #community (PANORAMIC): a RCT, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00431-6/fulltext?rss=yes

In a vaccinated population, people treated with molnupiravir for acute COVID19 felt better, experienced fewer & less severe symptoms, accessed health care less often, & took less time off work at 6 mos. However, absolute differences in this open-label design are small with high numbers needed to treat.

Health #outcomes 3 mos & 6 mos after #molnupiravir treatment for #COVID19 for people at higher #risk in #community (PANORAMIC): a RCT, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00431-6/fulltext?rss=yes

In a vaccinated population, people treated with molnupiravir for acute COVID19 felt better, experienced fewer & less severe symptoms, accessed health care less often, & took less time off work at 6 mos. However, absolute differences in this open-label design are small with high numbers needed to treat.

Health #outcomes 3 mos & 6 mos after #molnupiravir treatment for #COVID19 for people at higher #risk in #community (PANORAMIC): a RCT, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00431-6/fulltext?rss=yes

In a vaccinated population, people treated with molnupiravir for acute COVID19 felt better, experienced fewer & less severe symptoms, accessed health care less often, & took less time off work at 6 mos. However, absolute differences in this open-label design are small with high numbers needed to treat.

Health #outcomes 3 mos & 6 mos after #molnupiravir treatment for #COVID19 for people at higher #risk in #community (PANORAMIC): a RCT, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00431-6/fulltext?rss=yes

In a vaccinated population, people treated with molnupiravir for acute COVID19 felt better, experienced fewer & less severe symptoms, accessed health care less often, & took less time off work at 6 mos. However, absolute differences in this open-label design are small with high numbers needed to treat.

Health #outcomes 3 mos & 6 mos after #molnupiravir treatment for #COVID19 for people at higher #risk in #community (PANORAMIC): a RCT, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00431-6/fulltext?rss=yes

In a vaccinated population, people treated with molnupiravir for acute COVID19 felt better, experienced fewer & less severe symptoms, accessed health care less often, & took less time off work at 6 mos. However, absolute differences in this open-label design are small with high numbers needed to treat.

Triple #combination of #Remdesivir, #Molnupiravir & #Ribavirin is highly efficient in inhibiting #coronavirus #replication in #human nasal #airway epithelial cell cultures & in a #hamster infection model. Antiviral Res.: https://www.sciencedirect.com/science/article/pii/S0166354224002031?via%3Dihub

Combining Remdesivir, molnupiravir, & ribavirin increases the antiviral efficacy against coronavirus OC43. This triple therapy also eliminates #SARS-CoV-2 replication in #lungs of infected hamsters, unlike double combinations.

Triple #combination of #Remdesivir, #Molnupiravir & #Ribavirin is highly efficient in inhibiting #coronavirus #replication in #human nasal #airway epithelial cell cultures & in a #hamster infection model. Antiviral Res.: https://www.sciencedirect.com/science/article/pii/S0166354224002031?via%3Dihub

Combining Remdesivir, molnupiravir, & ribavirin increases the antiviral efficacy against coronavirus OC43. This triple therapy also eliminates #SARS-CoV-2 replication in #lungs of infected hamsters, unlike double combinations.

Triple #combination of #Remdesivir, #Molnupiravir & #Ribavirin is highly efficient in inhibiting #coronavirus #replication in #human nasal #airway epithelial cell cultures & in a #hamster infection model. Antiviral Res.: https://www.sciencedirect.com/science/article/pii/S0166354224002031?via%3Dihub

Combining Remdesivir, molnupiravir, & ribavirin increases the antiviral efficacy against coronavirus OC43. This triple therapy also eliminates #SARS-CoV-2 replication in #lungs of infected hamsters, unlike double combinations.

Triple #combination of #Remdesivir, #Molnupiravir & #Ribavirin is highly efficient in inhibiting #coronavirus #replication in #human nasal #airway epithelial cell cultures & in a #hamster infection model. Antiviral Res.: https://www.sciencedirect.com/science/article/pii/S0166354224002031?via%3Dihub

Combining Remdesivir, molnupiravir, & ribavirin increases the antiviral efficacy against coronavirus OC43. This triple therapy also eliminates #SARS-CoV-2 replication in #lungs of infected hamsters, unlike double combinations.

Triple #combination of #Remdesivir, #Molnupiravir & #Ribavirin is highly efficient in inhibiting #coronavirus #replication in #human nasal #airway epithelial cell cultures & in a #hamster infection model. Antiviral Res.: https://www.sciencedirect.com/science/article/pii/S0166354224002031?via%3Dihub

Combining Remdesivir, molnupiravir, & ribavirin increases the antiviral efficacy against coronavirus OC43. This triple therapy also eliminates #SARS-CoV-2 replication in #lungs of infected hamsters, unlike double combinations.

The triple #combination of #Remdesivir (GS-441524), #Molnupiravir and #Ribavirin is highly efficient in inhibiting #coronavirus #replication in human nasal #airway epithelial #cell cultures and in a hamster infection model http://biorxiv.org/cgi/content/short/2024.05.14.594200v1?rss=1

Our finding indicate that co-administration of approved drugs for treatment of CoVs infections should be further explored but also vs other families of viruses w/ epidemic and pandemic potential for which no effective antiviral treatment is available.

The triple #combination of #Remdesivir (GS-441524), #Molnupiravir and #Ribavirin is highly efficient in inhibiting #coronavirus #replication in human nasal #airway epithelial #cell cultures and in a hamster infection model http://biorxiv.org/cgi/content/short/2024.05.14.594200v1?rss=1

Our finding indicate that co-administration of approved drugs for treatment of CoVs infections should be further explored but also vs other families of viruses w/ epidemic and pandemic potential for which no effective antiviral treatment is available.

The triple #combination of #Remdesivir (GS-441524), #Molnupiravir and #Ribavirin is highly efficient in inhibiting #coronavirus #replication in human nasal #airway epithelial #cell cultures and in a hamster infection model http://biorxiv.org/cgi/content/short/2024.05.14.594200v1?rss=1

Our finding indicate that co-administration of approved drugs for treatment of CoVs infections should be further explored but also vs other families of viruses w/ epidemic and pandemic potential for which no effective antiviral treatment is available.

The triple #combination of #Remdesivir (GS-441524), #Molnupiravir and #Ribavirin is highly efficient in inhibiting #coronavirus #replication in human nasal #airway epithelial #cell cultures and in a hamster infection model http://biorxiv.org/cgi/content/short/2024.05.14.594200v1?rss=1

Our finding indicate that co-administration of approved drugs for treatment of CoVs infections should be further explored but also vs other families of viruses w/ epidemic and pandemic potential for which no effective antiviral treatment is available.

The triple #combination of #Remdesivir (GS-441524), #Molnupiravir and #Ribavirin is highly efficient in inhibiting #coronavirus #replication in human nasal #airway epithelial #cell cultures and in a hamster infection model http://biorxiv.org/cgi/content/short/2024.05.14.594200v1?rss=1

Our finding indicate that co-administration of approved drugs for treatment of CoVs infections should be further explored but also vs other families of viruses w/ epidemic and pandemic potential for which no effective antiviral treatment is available.

Randomized controlled #trial of #molnupiravir #SARS-CoV-2 viral and #antibody #response in at-#risk adult outpatients https://www.nature.com/articles/s41467-024-45641-0

-- In this clinical trial, the authors show that a 5-day molnupiravir treatment reduces SARS-CoV-2 viral load in at-risk outpatients by day 5 but mostly fails to clear virus, leads to lower spike antibody response by day 14 and higher virus mutation rates.

Randomized controlled #trial of #molnupiravir #SARS-CoV-2 viral and #antibody #response in at-#risk adult outpatients https://www.nature.com/articles/s41467-024-45641-0

-- In this clinical trial, the authors show that a 5-day molnupiravir treatment reduces SARS-CoV-2 viral load in at-risk outpatients by day 5 but mostly fails to clear virus, leads to lower spike antibody response by day 14 and higher virus mutation rates.